Intercept Pharmaceuticals

Rank#5664

Market Cap466.90M

CountryUnited States

Summary

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

History

Intercept Pharmaceuticals, Inc was founded in 2002 as a biopharmaceutical company located in New York, NY. Since its foundation, Intercept has been dedicated to researching and developing novel drugs to treat serious, life-threatening chronic liver diseases. Intercept's development of obeticholic acid (OCA) began in 2007 and was approved by the FDA in 2016 for the treatment of primary biliary cholangitis (PBC). The company has since developed and commercialised OCA for treating NASH, biliary atresia, and primary sclerosing cholangitis.

Mission

Our mission is to build a healthier tomorrow for patients with progressive non-viral liver diseases.

Vision

Intercept Pharmaceuticals' vision is to create a world where chronic liver diseases can be prevented or effectively managed.

References

https://en.wikipedia.org/wiki/Intercept_Pharmaceuticals

https://in.investing.com/equities/intercept-pharmaceuticals-inc

https://www.comparably.com/companies/intercept-pharmaceuticals/mission

https://www.crunchbase.com/organization/intercept-pharmaceuticals

https://finance.yahoo.com/quote/ICPT/

https://www.interceptpharma.com

Leadership team